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Abstract: The effects of a probiotic acidified milk product on the blood serum metabolite 
profile  of  patients  suffering  from  Irritable  Bowel  Syndrome  (IBS)  compared  to  a  
non-probiotic acidified milk product was investigated using 
1H NMR metabonomics. For 
eight weeks, IBS patients consumed 0.4 L per day of a probiotic fermented milk product or  
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non-probiotic acidified milk. Both diets resulted in elevated levels of blood serum L-lactate 
and 3-hydroxybutyrate. Our results showed identical effects of acidified milk consumption 
independent  of  probiotic  addition.  A  similar  result  was  previously  obtained  in  a 
questionnaire-based evaluation of symptom relief. A specific probiotic effect is thus absent 
both in the patient subjective symptom evaluations and at the blood serum metabolite level. 
However, there was no correspondence between symptom relief and metabolite response 
on the patient level. 
Keywords: metabonomics; 
1H-NMR spectroscopy; Irritable Bowel Syndrome; acidified 
milk products; multivariate data analysis; lactate; probiotics 
 
1. Introduction  
Irritable  Bowel  Syndrome  (IBS)  is  a  very  common  gastrointestinal  disorder  associated  with 
abdominal pain connected with defecation [1]. Abnormal defecation such as diarrhea and constipation 
along with distension are major symptoms, which do not coincide with demonstrable abnormalities [2]. 
Most patients manage to keep discomfort at a minimum by regular exercise, low-fat, fiber-rich diets, 
and medication. However, some patients suffer from severe symptoms that influence the quality of 
their everyday life such as travel over short distances and social life [3].  
During  the  past  decade,  several  studies  [4-9]  have  shown  that  consumption  of  probiotics  has 
positive effects on gastrointestinal inflammation, thereby conferring benefits to people suffering from 
IBS. These effects  have been  identified using symptom questionnaires in  combination with either 
measurements  of  colonic  transit  [4]  or  collection  of  fecal  and  blood  samples  [7-10].  Intake  of 
probiotics has also shown to delay the first onset of pouchitis and to improve the general quality of life 
for patients undergoing ileal pouch-anal anastomosis [5,6]. High placebo response is reported based on 
questionnaires [10-13], which raises the question of the placebo product or the probiotic delivering 
matrix having an influence in itself.  
Over the past few years, metabonomics based on proton NMR (
1H NMR) coupled with multivariate 
data  analysis  has  proven  to  be  an  extremely  powerful  method  for  determination  of  variations  in 
metabolite  concentrations  within  data  collected  from  large  numbers  of  samples  [14-16].  With  a 
minimum of sample preparation, high reproducibility [17], and short experimental time, it can be 
considered a  superior  approach  providing  dietary  intervention  studies  with  a  tool  for  detection  of 
metabolite changes associated with the experimental diet.  
As  a  secondary  investigation  within  a  project  where  blood  serum  samples  from  IBS  patients 
enrolled in a large controlled double-blind diet intervention study [10] were collected, the aim of the 
present study was to investigate the influence of the consumption of acidified milk products with 
probiotics  on  the  blood  serum  metabolite  composition.  Using  a  metabonomic  approach  based  on 
1H NMR spectroscopy coupled with multivariate statistical analysis, we analyzed the change in the 
blood serum metabolite profile in IBS patients caused by intake of either a probiotic fermented milk 
product or a non-probiotic acidified milk product.  Nutrients 2010, 2  
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2. Experimental Section 
2.1. Study participants and design  
An  initial  group  of  volunteer  IBS  patients  was  enrolled  in  the  study  based  on  the  Rome  II 
criteria [18]. Patients were then followed for two weeks to establish whether they truly matched the 
Rome II criteria and to study symptom severity. Symptoms were scored according to the IBS severity 
scoring  system  (SSI)  [19].  Study  inclusion  required  that  the  patients  had  to  score  VAS  (Visual 
Analogue Scale) > 40 on at least one of five questions of the IBS SSI questionnaires and to have a lack 
of adequate relief of the IBS symptoms the week before inclusion. Patients not fulfilling these criteria 
were excluded from the study, leaving a final group of 74 subjects. Subjects were randomized for one 
of two treatments. During the intervention period, seven subjects dropped out for reasons unrelated to 
the study. For different reasons, blood serum samples were not acquired from six subjects, leaving a 
total of 61 subjects in the final group completing the study. This total patient group consisted of 
45 females and 16 males aging from 18 to 79 years with a mean of 42.5 years. Data on age, BMI, 
gender, time with IBS and type of IBS for the patients per group was collected (see additional file: 
Supplementary  Table  1).  All  patients  gave  their  informed  consent.  The  study  was  performed  in 
accordance  with  the  Declaration  of  Helsinki  II  and  approved  by  the  Ethics  Committee  of  the 
University of Gothenburg. The trial was registered at ClinicalTrial.gov with the registration number: 
NCT01127828.  
2.2. Dietary treatment and sample collection  
Two different dietary treatments consisting of a fermented dairy product containing probiotics and a 
chemically  acidified  milk  product,  respectively,  were  used.  The  probiotic  acidified  milk  product 
(Cultura
©,  Arla  Foods  amba,  Denmark)  was  produced  by  fermentation  of  homogenized,  
high-pasteurized,  low-fat  (1.5%)  milk  by  the  use  of  two  fermentation  starter  cultures, 
Lactobacillus delbruckeii ssp. bulgaricus and Streptococcus thermophilus and the inclusion of three 
probiotic  strains,  Lactobacillus  paracasei  F19,  Lactobacillus  acidophilus  LA-5  and 
Bifidobacterium lactis  BB-12,  at  concentrations  of  5  ×  10
7  CFU/mL  (see  additional  file: 
Supplementary  Table  2).  The  chemically  acidified  product  was  produced  by  acidification  of 
homogenized,  high-pasteurized,  low-fat  (1.5%)  milk  by  addition  of  D-(+)-gluconic  acid  ʴ-lactone 
(≥99.0%)  (GDL)  (Sigma-Aldrich,  Seelze,  Germany;  see  additional  file:  Supplementary  Table  2). 
Addition of GDL mimics the slow pH reduction created during fermentation and produces a product 
comparable to the probiotic product in taste, texture and color. Both products had a pH value of 4.5. 
Before entering the study, patients had a wash-out period where they did not consume any acidified 
milk  products  for  a  2-week  period.  After  this  period,  the  two  patient  groups  were  instructed  to 
consume 0.4 L per day, divided in two takings of 0.2 L, of either the GDL-acidified milk product 
(n = 31) or the probiotic acidified milk product (n = 30) over an 8-week period. In this report, the two 
products will be referred to as the GDL milk product and the probiotic milk product. During the 
intervention period, patients were instructed not to consume any other fermented dairy products. Blood 
samples were collected, the body weight measured, and intake of energy, protein, fat, carbohydrates, Nutrients 2010, 2  
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calcium, and fiber in a 3-day period were recorded (Table 1) for each subject one day before the trial 
started (baseline) and after the last day of the trial period (post treatment).  
Table 1. Summary of 3-day energy intake record by IBS patients before sample collection 
a 
and IBS patients’ body weight measurements. Patient data from samples included in the 
1H-NMR study. 
Nutrient  GDL milk product 
b  Probiotic milk product 
c 
Energy, kJ/(kg body wt) 
d     
Baseline  31.07 ±  1.57  28.25 ±  1.50 
Post treatment  27.78 ±  1.86 *  24.24 ±  1.25 * 
Protein, g/(kg body wt)     
Baseline  1.22 ±  0.08  1.12 ±  0.05 
Post treatment  1.04 ±  0.07 *  0.95 ±  0.04 * 
Fat, g/(kg body wt)     
Baseline  1.21 ±  0.09  1.04 ±  0.07 
Post treatment  0.98 ±  0.09 *  0.89 ±  0.05 * 
Carbohydrates, g/(kg body wt)     
Baseline   3.62 ±  0.18  3.34 ±  0.19 
Post treatment  3.31 ±  0.23 *  2.89 ±  0.19 * 
Calcium, mg/(kg body wt)     
Baseline  16.06 ±  1.19  13.71 ±  1.14 
Post treatment  12.68 ±  1.24 *  10.07 ±  1.00 * 
Fiber, g/(kg body wt)     
Baseline  0.31 ±  0.02  0.26 ±  0.01 
Post treatment  0.26 ±  0.03 *  0.21 ±  0.01 * 
Weight, kg     
Baseline  73.13 ±  2.58  72.17 ±  2.74 
Post treatment  74.11 ±  2.75 *  72.51 ±  2.74 
a Nutritional data are given as mean ±  SEM of summed 3-day nutritional intake. Baseline data was 
obtained 1 day before initiation of the intervention period and post treatment data was collected on 
the last day of the intervention period. Body weight measurements are given as mean ±  SEM. Post 
treatment means marked with * differ significantly from baseline (P ≤ 0.05);  
b n = 28. One patient failed to record nutritional data before collection of the baseline sample and 
was therefore left out of the analysis;  
c n = 29. One patient failed to record nutritional data before collection of the post treatment sample 
and was therefore left out of the analysis;  
d Patient energy intake at baseline and post treatment differed not significantly (P > 0.05) between 
GDL milk product and probiotic milk product patient groups. 
The patients fasted overnight and then consumed a fiber-rich non-dairy meal (Content: 2258 kJ; 
36% fat, 15% proteins, 49% carbohydrates; 9.2 g fiber) 1 h before collection of blood. The meal was 
given to the patients to study possible symptom relief induced by the consumption of the two different 
acidified milk products. Blood serum was prepared by collecting 5 mL blood from the antecubital vein 
in  silicon-treated  Vacutainer
®  tubes.  The  blood  was  left  to  clot  for  30  min  followed  by  20  min 
centrifugation at 1600 ×  g. The serum fraction was collected and stored in aliquots at −70 ° C.  Nutrients 2010, 2  
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2.3. D- and L-lactate measurements 
Five GDL milk group and six probiotic milk group baseline samples and their corresponding post 
treatment samples were randomly selected for lactate isomer analysis. Proteins larger than 10 kDa 
were removed by filtrating 250 μL of each sample using a Microcon 10-YM Centrifugal Filter Unit 
(Millipore, Billerica, USA) according to the manufacturer’s protocol. D- and L-lactate concentrations 
were measured using a D-lactic acid/L-lactic acid kit (Boeringer Ingelheim GmbH, Ingelheim am Rein, 
Germany) according to the manufacturer’s protocol. 
2.4. Sample preparation and 
1H NMR analysis  
Serum  samples  were  prepared  by  adding  D2O  (serving  as  a  spectrometer  frequency  lock)  into 
200 µ L of serum to a total volume of 600 µ L. 
1H NMR measurements were performed on a Bruker 
Avance II 700 spectrometer (Bruker Biospin, Rheinstetten, Germany), with a standard 
1H detection 
5 mm  HCN  triple  resonance  probe,  at  25  ° C  and  with  a 
1H  frequency  of  700.09  MHz  (16.4  T). 
1H spectra  were  acquired  using  a  single-90° -pulse  experiment  with  a  Carr–Purcell–Meiboom–Gill 
(CPMG) delay. The CPMG delay removes broad signals from high-molecular-weight molecules that 
would  otherwise  complicate  interpretation  of  the  spectra.  Total  CPMG  delay  was  40  ms  and  the 
spin-echo delay 200 µ s. Water was suppressed by presaturation of the water peak during the relaxation 
delay of 1.5 s. A total of 128 transients of 16 K data points spanning a spectral width of 24 ppm were 
collected. Experimental time for collection of one spectrum was 5 min. For assignment purposes, a 
two-dimensional (2D) 
1H-
1H TOtal Correlation SpectroscopY (TOCSY) spectrum [20] with 80 ms 
mixing was acquired on a representative sample. 
2.5. Data processing and statistical analysis 
Processing of 
1H NMR spectra was performed using the iNMR software (Nucleomatica, Molfetta, 
Italy). An exponential line-broadening of 0.5 Hz was applied to the free induction decay (FID) before 
Fourier transformation. All acquired spectra were referenced to the CH3 chemical shift of alanine at 
1.466  ppm.  Data  reduction  of  the 
1H  NMR  spectra  was  performed  by  dividing  the  spectra  into 
0.01 ppm regions, so-called bins. Each bin was then integrated to obtain the total signal intensity. The 
region from 10.00–0.00 ppm, except for the region comprising the water signal (5.11–4.66 ppm), was 
used for analysis. Normalization to total intensity of the spectrum was performed before further data 
analysis. Cross-validated principal component analysis (PCA) was performed on mean-centered data 
to identify discrete patterns. PCA reduces the dimensionality of a data set by finding a new set of 
variables, smaller than the original set of variables, and retains most of the sample’s information. The 
new variables, called principal components, are uncorrelated, and are ordered by the fraction of the 
total information they explain. Each principal component is described by a loading vector, like an 
NMR spectrum with positive and negative peaks, and scores that describe how much the loading 
vector contributes to the spectrum of each sample. The scores can be used to identify similarities and 
differences  between  samples.  Patterns  identified  by  PCA  were  subsequently  analyzed  by 
cross-validated orthogonal-projection to latent structures-discriminant analysis (OPLS-DA) [21]. In the 
cross validated OPLS-DA algorithm, the variation in the 
1H NMR data is decomposed into three parts: Nutrients 2010, 2  
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the  variation  of  the  data  correlated  to  the  discriminant  class,  the  specific  systemic  variation  not 
correlating to the discriminant  matrix  and the residual  variation.  Thereby a  model with  minimum 
predictive components defined by the number of degrees of freedom between group variances was 
produced. Cross validation was performed by removing every seventh sample and the new data set was 
used to predict the excluded samples. The process was replicated until each sample had been removed 
at least once. The optimal number of components is based on the cross validation test and the value 
Q
2(cum)  describes  the  predictability  of  the  model.  When  performing  OPLS-DA  on  the 
1H  NMR 
spectral data, unit variance scaling was applied to allow signals of lower intensity to exert the same 
weight  on  the  model  as  higher-intensity  signals.  To  facilitate  interpretation  of  the  OPLS-DA 
covariances (loadings), back-scaling transformation and presentation as a limit discriminant weight 
plot were applied. Back-scaling was performed by calculation of the covariances between each bin and 
the predictive component scores. 
The significance of each bin, and thereby the individual metabolites, was elucidated by calculation 
of the correlation coefficient of each bin and the corresponding predictive component score. Limit 
discriminant weight plots were then produced and these plots present covariances of variables where 
variables with a correlation coefficient squared, R
2, to the class discrimination higher than 0.60 are 
highlighted. Multivariate data analysis was performed using the Simca-P 11.5 software (Umetrics, 
Umeå , Sweden).  
Data  on  record  of  3-day  dietary  intake,  body weight,  and  lactate  measurements  were  analyzed 
statistically by paired t tests. One-way ANOVA was used for analyzing PCA scores for differences 
between baseline and post treatment samples. An unpaired t test was performed to analyze age and 
BMI  differences  between  the  two  treatment  groups.  All  tests  were  performed  using  the 
0.05 significance level. 
3. Results 
Human blood serum spectra were assigned by comparison of chemical shifts in a representative 
spectrum (Figure 1) to established libraries reported in the literature [22-25], the Human Metabolome 
Data Base (HMDB) [26], and confirmed by cross-peak assignment in the 2D TOCSY spectrum. The 
1H NMR spectra contained 22 assignable metabolites including amino acids, lipids, organic acids, 
glycoproteins, and glucose (Table 2). Visual inspection of all spectra revealed no general, obvious 
differences in metabolite composition between samples. However, one GDL baseline sample displayed 
an atypical spectrum with broad and strong peaks and extra peaks assigned to lipid metabolites. Data 
regarding nutritional intake, disease or medication could not account for this atypical appearance. This 
sample and the corresponding post treatment sample were therefore discarded from further analysis.  
With the aim of identifying more discrete patterns and changes, multivariate data analysis was 
performed. PCA revealed another GDL baseline sample outlier, due to very large and broad lipid 
signals. This  sample,  together  with its complementary post treatment sample, was discarded from 
further  analysis  to  avoid  distortion  of  the  multivariate  data  models.  Thus,  the  resulting  dataset 
contained 58 samples from 29 patients in the GDL milk group and 60 samples from 30 patients in the 
probiotic milk group. In order to investigate the variation in the baseline and post treatment samples, 
PCA was performed on the GDL milk and the probiotic milk baseline and post treatment groups, Nutrients 2010, 2  
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respectively (see additional file: Supplementary Figures 1 and 2). The PCA scores were tested for 
groupings according to gender, age and BMI (data not shown). No patterns were detected in either of 
the  groups  in  any  of  the  performed  tests.  We  also  tested  for  treatment  response.  Although  this 
subgroup had shown symptom relief in both treatment groups [10], no distinction could be made 
between  responders  and  non-responders  based  on  blood  serum  metabolite  composition  (data  not 
shown).  The  tests  were  repeated  using  OPLS  and  OPLS-DA  without  detecting  any  correlations. 
Accordingly,  the  results  demonstrated  that  each  group  could  be  considered  as  one,  containing  no 
sub groupings.  
Figure 1. 
1H NMR CPMG spectrum of human blood serum from a patient suffering from 
IBS. The key is given in Table 2. 
 
Table 2. Assignments of observed 
1H-NMR peaks in blood serum of a patient suffering from IBS. 
Key  Metabolite  δ 1H (multiplicity)  Moieties 
1  Histidine  7.74 (s), 7.03 (s)  CH, CH 
2  Tyrosine  7.17 (m), 6.87 (m)  CH, CH 
3  Urea  5.76 (s)  NH2 
4  Unsaturated lipids in serum  5.28 (m)  -CH=CH- 
5  ʱ-Glucose  5.22 (d), 3.82 (m), 3.71 (t), 3.52 (d)  C-H1, C-H6, C-H3, C-H2 
6  β-Glucose 
4.63 (d), 3.89 (d), 3.47 (d), 3.40 (t), 
3.23 (d) 
C-H1, C-H6, C-H5, C-H4, C-H2 
7  Lactate  4.10 (q), 1.32 (d)  ʱCH, βCH3 
8  Creatine  3.92 (s), 3.04 (s)  CH2, NCH3 
9  Glycerol  3.88 (m), 3.65 (d)  CH, CH2 
10  Leucine  3.70 (m), 0.96 (d)  ʱCH, γCH3 
11  Valine  3.60 (d), 1.03 (d), 0.97 (d)  ʱCH, γCH3, ʴCH3 
12  Proline  3.44 (t)  ʴCH2 
13  Choline  3.21 (s)  N(CH3)3 
14  Lipid 
2.73 (m), 1.56 (m), 1.25 (m), 
0.84 (m) 
C=CCH2C=C, CH2CH2CO, (CH2)n, 
CH3(CH2)n 
15  Glutamine  2.43 (m)  γCH2 
16  3-hydroxybutyrate  2.34 (m), 1.20 (d)  ʱCH2, βCH3 
17  Acetoacetate  2.21 (s)  CH3 
18  Glutamate   2.10 (m)  βCH2 Nutrients 2010, 2  
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Table 2. Cont. 
19  N-acetyl glycoproteins  2.03 (s)  CH3 
20  Lysine  1.88 (m), 1.72 (m)  βCH2, ʴCH2 
21  Alanine  1.46 (d)  βCH3 
22  Isoleucine  0.99 (t)  βCH3 
After establishing that baseline and post treatment groups had no sub-groupings, PCA was carried 
out on the sample sets containing both baseline and post treatment samples (Figure 2). For both the 
GDL acidified milk group and the probiotic milk group principal component 2 showed a significant 
separation of baseline and post treatment samples using one-way ANOVA. Both the GDL and the 
probiotic treatment groups showed a similar discrimination of baseline and post treatment samples. To 
identify the difference between baseline and post treatment samples, cross validated OPLS-DA was 
conducted in parallel on the GDL acidified and probiotic milk group using baseline and post treatment 
as the discriminant matrix (see additional file: Supplementary Figure 3). 
Figure 2. PCA score plot of baseline and post treatment samples (a) GDL acidified milk 
patient group baseline and post treatment samples (n = 58). R
2X(1) = 0.516, R
2X(2) = 0.178 
and Q
2(cum) = 0.941; (b) Probiotic milk patient group baseline and post treatment samples 
(n = 60). R
2X(1) = 0.556, R
2X(2) = 0.200 and Q
2(cum) = 0.928. Post treatment different 
from baseline, P ≤ 0.05. R
2X describes how much of the variance that is explained by the 
component. Q
2(cum) represents the predictability of the total model and is related to the 
statistical validity of the model. 
 
High  R
2X  (GDL  R
2X(cum)  =  0.821  and  probiotic  R
2X(cum)  =  0.833)  and  Q
2  values  (GDL 
Q
2(cum) = 0.841 and probiotic Q
2(cum) = 0.848) using one predictive and four orthogonal components 
in  both  analyses  reveals  statistically  robust  and  highly  predictable  models.  A  clear  discrimination 
between the baseline and post treatment groups indicated that a large majority of the patients had 
consumed their prescribed experimental diet satisfactorily. In order to identify metabolites responsible 
for the separation between baseline and post treatment samples, OPLS-DA loadings were evaluated by 
calculating the correlation and the covariance for each variable with the OPLS-DA predictive scores. 
The resulting plots display the variable covariances (Figure 3).  Nutrients 2010, 2  
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Figure  3.  Metabolite  identification  based  on  limit  discriminant  weight  plots.  Limit 
discriminant weight plots of back-scaled OPLS-DA data from GDL milk and probiotic 
milk treated patient groups with variable covariances presented with different R
2 cut-off 
values.  (a)  GDL  acidified  milk  group;  (b)  Probiotic  milk  group.  Peak  at  ʴ  1.32  ppm 
represents the βCH3 of lactate and the peak at ʴ 4.10 ppm represents the ʱCH of lactate. The 
peak at ʴ 2.34 ppm represents the ʱCH2 proton of 3-hydroxybutyrate. Grey spectra show all 
covariances and black spectra have a cut-off value R
2 > 0.6. 
 
The  plots  show  variables  that  are  significantly  correlated  (R
2  >  0.6,  black  spectra)  with  the 
separation of baseline and post treatment samples. The results for the GDL milk group and for the 
probiotic milk group are virtually identical. In both plots, three peaks showed high correlations with 
the discrimination; the ʱCH of lactate at 4.10 ppm, the ʱCH2 proton of 3-hydroxybutyrate at 2.34 ppm 
and the βCH3 of lactate at 1.32 ppm. No other metabolites had R
2 values higher than 0.45, emphasizing 
that  lactate  and  3-hydroxybutyrate  were  particularly  important  for  the  effect  induced  by  the  two 
treatment  types.  Both 
1H  NMR  proton  signals  from  lactate  were  present.  Only  the  ʱCH2  from 
3-hydroxybutyrate had a high correlation in the discriminant weight plot due to overlap of the βCH3 
with  large  lipid  signals  around  1.20  ppm.  Positive  covariances  show  that  the level  of  lactate  and 
3-hydroxybutyrate was higher in the post treatment samples than in the baseline samples. The relative 
concentrations of lactate and 3-hydroxybutyrate as measured by the intensity of the signals in the NMR 
spectra are shown in Figure 4. To confirm that lactate was responsible for the separation between 
baseline and post treatment samples, the relevant variables were extracted and used for PCA. Both in 
the GLD milk group and the probiotic milk group clear separation of baseline and post treatment 
samples were observed in PCA score plots when only using variables for lactate (data not shown). 
To  further verify  the  higher  lactate  levels  in the  post  treatment  samples,  a  standard  enzymatic 
analysis of the lactate concentration was performed (Figure 5). The lactate analysis determines the  
D-  and  L-isomer  concentrations  separately  [27,28].  We  found  increased  levels  of  L-lactate  in  post 
treatment samples of both treatment groups. No increase in  D-lactate levels was found. Lactic acid 
bacteria can produce both lactate isomers and the body produces L-lactate. Based on our results, we 
can, therefore, only verify the increase in L-lactate but not conclude where the increase in L-lactate 
stems from.  Nutrients 2010, 2  
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We tested for a probiotic effect by performing PCA and OPLS-DA on the difference between the 
post- and pre-treatment spectra (to remove baseline individual variation). This analysis did not reveal 
any difference in the response for the probiotic and GDL milk products. Nor were we able to see 
effects of gender, BMI, or a correlation with symptom relief [10] at this level. 
Figure  4.  Relative  concentration  of  lactate  and  3-hydroxybutyrate  based  on  signal 
intensity. (a) Lactate; (b) 3-hydroxybutyrate. Boxes represent 25th to 75th percentile of 
data and whiskers represent data spread. Asterisk (*) indicate that post treatment value is 
significantly different from baseline, P ≤ 0.05. 
 
Figure  5.  D-  and  L-lactate  measurements.  GDL acidified milk patient group  (n  = 10). 
Probiotic milk patient group (n = 12). (a) L-lactate; (b) D-lactate. Boxes represent 25th to 
75th percentile of data and whiskers represent data spread. Asterisk (*) indicate that post 
treatment value is significantly different from baseline, P ≤ 0.05. Please note the different 
scales in (a) and (b). 
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4. Discussion  
By employing 
1H NMR spectroscopy in combination with multivariate data analysis, we revealed 
that consumption of 0.4 L of probiotic acidified milk product a day for eight weeks led to a change in 
the overall blood serum metabolite composition in IBS patients that was not different from that of 
non-probiotic acidified milk. Since the experiment was designed to detect effects of probiotics in the 
context of an acidified milk product, and not the effect of the acidified milk itself, we cannot rule out 
effects from other factors. However, the clear and identical response in both treatment groups suggests 
a response to the delivering vector. We identified elevated levels of blood serum (L-) lactate and 
3-hydroxybutyrate after both treatments.  
The IBS patients enrolled in the present study consumed no probiotic dairy products during the 
two-week wash-out period before entering the diet intervention period. Thus, the baseline samples 
correspond to a diet without any probiotic dairy products included. Under normal conditions, blood 
serum lactate levels are kept at a constant flux level in a dynamic process where cells release and take 
up lactate at a rate that depends on the metabolic rate of resting or exercising muscles [29-32]. 
Lactate ingested by consumption of the prescribed diet would thus be quickly removed after a 
meal [33,34]. The meal consumed one hour before both the baseline and the post treatment sample 
collection was devoid of dairy products. The observed effect was therefore independent of the meal 
consumed before sample collection.  
We  identified  the  rise  in  lactate  as  a  rise  in  the  level  of  L-lactate.  The  elevated  levels  of 
3-hydroxybutyrate observed in both the GDL and the probiotic milk group can be correlated to the 
elevated L-lactate levels (R = 0.76 and R = 0.71 based on peak intensity, for the GDL treatment, and 
probiotic treatment groups, respectively),  as  conversion  of lactate to glucose  in  the  liver removes 
oxaloacetate  from  the  tricarboxylic  acid  (TCA)  cycle,  which  thereby  reduces  the  utilization  of 
acetyl-CoA.  Excess  acetyl  CoA  will  then  be  converted  into  ketone  bodies  such  as 
3-hydroxybutyrate [35-37].  
During the intervention period, symptom relief scores were recorded for all patients showing that a 
subgroup of the patients receiving the probiotic milk product experienced a faster relief in symptoms 
than  patients  receiving  the  GDL  milk  product.  As  the  intervention  progressed,  the  difference  in 
symptom relief was balanced, and after eight weeks no discrimination between the two treatment types 
was found [10]. In this perspective, it is very interesting to see that we could not discriminate between 
the effects of added probiotics and GDL after eight weeks intervention. Symptom scores are subjective 
and based on the patient’s own evaluation, and high degrees of placebo response have been reported in 
diet  intervention  studies  concerning  bowel  disorders  [11-13].  Our  results  might  suggest  that  the 
delivering  matrix,  in  this  case  acidified  milk,  can  have  an  influence  on  symptom  relief  in  these 
patients. Although symptom relief only was observed for a subgroup of responders, the effect of the 
treatments at blood serum metabolite level was observed for the total patients in both treatment groups, 
and no correlations between symptom relief and metabolite response was observed. We can conclude 
that  both  responders  and  non-responders  on  both  diets  have  similar  serum  levels  of  lactate  and 
3-hydroxybutyrate after the intervention period, when the same level of symptom relief is observed for 
both  diets.  We  were  not  able  to  find  any  correlation  between  the  elevated  levels  of  lactate  and 
3-hydroxybutyrate and the symptom relief score, Thus, we cannot at this point state whether the serum Nutrients 2010, 2  
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metabolite response is directly related to the relief-causing mechanism or not. For this, further studies 
with samples taken throughout the intervention period are needed. 
Both patients that received the GDL acidified milk product and patients that received the probiotic 
milk product had higher levels of blood serum lactate. Thus, the increase in lactate was independent of 
the presence of probiotics in the milk product. Reports have shown that a subgroup of IBS patients has 
an increased intestinal permeability [38-40], and paracellular permeability has also been linked to  
IBS  [41,42].  Gut  permeability  caused  by  the  syndrome  could  affect  the  lactate  absorption.  An 
increased production of lactate as a consequence of increased growth of intestinal lactic acid bacteria 
would lead to a higher serum level of lactate. Larger amounts of lactic acid-producing bacteria in the 
intestine, and hence more blood serum lactate, could be a result of either the large amounts of lactic 
acid bacteria consumed by the patients in the probiotic milk group, or of a favorable environment for 
native lactic acid-producing bacteria created by the intake of acidified milk products. Dietary records 
showed that patients clearly had a lower energy intake at the end of the trial period compared to before 
baseline  samples  were  collected.  However,  patients  consuming  the  GDL  acidified  product  gained 
weight during the trial, while patients consuming the probiotic milk product neither gained nor lost 
weight during the trial period (Table 1). We did not observe any changes in lipid metabolite profiles 
indicating a response caused by the GDL treatment. Furthermore, we found the changes in metabolite 
profile after an eight week intervention period were identical for the two treatment types. We therefore 
propose that the observed metabolite changes were independent of the lower energy intake.  
5. Conclusions  
Although no serum metabolite response to the probiotic diet intervention was found and the study 
did not contain any control for the effect of acidified milk, our results suggest that the delivering vector 
has an effect in itself. This means that it is very important to consider the delivering vector, when 
conducting probiotic diet intervention studies. The study revealed that the consumption of an acidified 
milk product gave rise to elevated levels of serum lactate and of 3-hydroxybutyrate, which we suggest 
to  be  a  product  of  the  high  lactate  condition  observed  after  the  intervention  period.  A  lacking 
discrimination between the effects of the two diets is in good agreement with the questionnaire-based 
health-status results, though no correlations between symptoms relief and serum metabolite response 
was found. 
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